LVAD Pulsatility Assesses Cardiac Contractility: In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation

Philemon Mikail, Jessica R. Crosby, Marvin J Slepian, Richard Smith, Zain I Khalpey

Research output: Contribution to journalArticle

Abstract

There is a need for a consistent, reproducible, and cost-effective method of determining cardiac recovery in patients who receive emerging novel therapeutics for advanced and end-stage heart failure (HF). With the increasing use of ventricular assist devices (VADs) in end-stage HF, objective device diagnostics are available for analysis. Pulsatility, one of the accessible diagnostic measures, is a variable gage of the differential between peak systolic and minimum diastolic flow during a single cardiac cycle. Following implantation of the VAD, HeartWare's HVAD records pulsatility regularly. Thus, we hypothesize that this measurement relates to the contractility of the heart and could be utilized as a metric for determining patient response to various therapeutics. In this study, therefore, we develop a translatable and effective predictive model characterizing pulsatility to determine HF status and potential HF recovery using the SynCardia Total Artificial Heart (TAH) in conjunction with a Donovan Mock Circulation System to create a simulation platform for the collection of pulsatility data. We set the simulation platform to patient conditions ranging from critical heart failure to a normal operating condition through the variation preload, afterload, and left ventricular (LV) pumping force or TAH "contractility." By manipulating these variables, pulsatility was found to accurately indicate significant (p < 0.05) improvements in LV contractility at every recorded afterload and preload, suggesting that it is a valuable parameter for the assessment of cardiac recovery in patients.

Original languageEnglish (US)
Pages (from-to)580-586
Number of pages7
JournalASAIO journal (American Society for Artificial Internal Organs : 1992)
Volume65
Issue number6
DOIs
StatePublished - Aug 1 2019

Fingerprint

Artificial heart
Artificial Heart
Heart Failure
Myocardial Contraction
Heart-Assist Devices
Recovery
Gages
In Vitro Techniques
Costs and Cost Analysis
Equipment and Supplies
Therapeutics
Costs

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

LVAD Pulsatility Assesses Cardiac Contractility : In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation. / Mikail, Philemon; Crosby, Jessica R.; Slepian, Marvin J; Smith, Richard; Khalpey, Zain I.

In: ASAIO journal (American Society for Artificial Internal Organs : 1992), Vol. 65, No. 6, 01.08.2019, p. 580-586.

Research output: Contribution to journalArticle

@article{385650f4241547cbb2658457f769b0cb,
title = "LVAD Pulsatility Assesses Cardiac Contractility: In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation",
abstract = "There is a need for a consistent, reproducible, and cost-effective method of determining cardiac recovery in patients who receive emerging novel therapeutics for advanced and end-stage heart failure (HF). With the increasing use of ventricular assist devices (VADs) in end-stage HF, objective device diagnostics are available for analysis. Pulsatility, one of the accessible diagnostic measures, is a variable gage of the differential between peak systolic and minimum diastolic flow during a single cardiac cycle. Following implantation of the VAD, HeartWare's HVAD records pulsatility regularly. Thus, we hypothesize that this measurement relates to the contractility of the heart and could be utilized as a metric for determining patient response to various therapeutics. In this study, therefore, we develop a translatable and effective predictive model characterizing pulsatility to determine HF status and potential HF recovery using the SynCardia Total Artificial Heart (TAH) in conjunction with a Donovan Mock Circulation System to create a simulation platform for the collection of pulsatility data. We set the simulation platform to patient conditions ranging from critical heart failure to a normal operating condition through the variation preload, afterload, and left ventricular (LV) pumping force or TAH {"}contractility.{"} By manipulating these variables, pulsatility was found to accurately indicate significant (p < 0.05) improvements in LV contractility at every recorded afterload and preload, suggesting that it is a valuable parameter for the assessment of cardiac recovery in patients.",
author = "Philemon Mikail and Crosby, {Jessica R.} and Slepian, {Marvin J} and Richard Smith and Khalpey, {Zain I}",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/MAT.0000000000000861",
language = "English (US)",
volume = "65",
pages = "580--586",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - LVAD Pulsatility Assesses Cardiac Contractility

T2 - In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation

AU - Mikail, Philemon

AU - Crosby, Jessica R.

AU - Slepian, Marvin J

AU - Smith, Richard

AU - Khalpey, Zain I

PY - 2019/8/1

Y1 - 2019/8/1

N2 - There is a need for a consistent, reproducible, and cost-effective method of determining cardiac recovery in patients who receive emerging novel therapeutics for advanced and end-stage heart failure (HF). With the increasing use of ventricular assist devices (VADs) in end-stage HF, objective device diagnostics are available for analysis. Pulsatility, one of the accessible diagnostic measures, is a variable gage of the differential between peak systolic and minimum diastolic flow during a single cardiac cycle. Following implantation of the VAD, HeartWare's HVAD records pulsatility regularly. Thus, we hypothesize that this measurement relates to the contractility of the heart and could be utilized as a metric for determining patient response to various therapeutics. In this study, therefore, we develop a translatable and effective predictive model characterizing pulsatility to determine HF status and potential HF recovery using the SynCardia Total Artificial Heart (TAH) in conjunction with a Donovan Mock Circulation System to create a simulation platform for the collection of pulsatility data. We set the simulation platform to patient conditions ranging from critical heart failure to a normal operating condition through the variation preload, afterload, and left ventricular (LV) pumping force or TAH "contractility." By manipulating these variables, pulsatility was found to accurately indicate significant (p < 0.05) improvements in LV contractility at every recorded afterload and preload, suggesting that it is a valuable parameter for the assessment of cardiac recovery in patients.

AB - There is a need for a consistent, reproducible, and cost-effective method of determining cardiac recovery in patients who receive emerging novel therapeutics for advanced and end-stage heart failure (HF). With the increasing use of ventricular assist devices (VADs) in end-stage HF, objective device diagnostics are available for analysis. Pulsatility, one of the accessible diagnostic measures, is a variable gage of the differential between peak systolic and minimum diastolic flow during a single cardiac cycle. Following implantation of the VAD, HeartWare's HVAD records pulsatility regularly. Thus, we hypothesize that this measurement relates to the contractility of the heart and could be utilized as a metric for determining patient response to various therapeutics. In this study, therefore, we develop a translatable and effective predictive model characterizing pulsatility to determine HF status and potential HF recovery using the SynCardia Total Artificial Heart (TAH) in conjunction with a Donovan Mock Circulation System to create a simulation platform for the collection of pulsatility data. We set the simulation platform to patient conditions ranging from critical heart failure to a normal operating condition through the variation preload, afterload, and left ventricular (LV) pumping force or TAH "contractility." By manipulating these variables, pulsatility was found to accurately indicate significant (p < 0.05) improvements in LV contractility at every recorded afterload and preload, suggesting that it is a valuable parameter for the assessment of cardiac recovery in patients.

UR - http://www.scopus.com/inward/record.url?scp=85070801672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070801672&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000861

DO - 10.1097/MAT.0000000000000861

M3 - Article

C2 - 30074963

AN - SCOPUS:85070801672

VL - 65

SP - 580

EP - 586

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 6

ER -